Concomitant Use of Sodium-Glucose Cotransporter 2 Inhibitors and Overactive Bladder Drugs and the Risk of Urinary Tract Infection
This study found a similar risk of UTIs in concomitant users of SGLT-2i and DPP-4i (weighted HR 1.08, 95% confidence interval: 0.88-1.32) with OAB drugs. In the second cohort, 2,387 and 280 new-users of SGLT-2i and GLP-1RA with OAB drugs were identified, respectively. Initiation of SGLT-2i while on OAB treatment was not associated with increased risk of UTI (0.89, 0.50-1.60), compared with initiation of GLP-1RA. These results show that the concomitant use of SGLT-2i with OAB drugs was not associated with an increased risk of UTI compared with the concomitant use of DPP-4i or GLP-1RA with OAB drugs.PMID:38284421 | DOI:10.1002/cpt.3182
Source: Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Sungho Bea Hyesung Lee Sohee Park Young Min Cho Won Suk Choi Katsiaryna Bykov Ju-Young Shin Source Type: research
More News: Cystitis | Drugs & Pharmacology | Overactive Bladder | Overactive Bladder Syndrome | Pyelonephritis | Sodium | Study | Urinary Tract Infections